Vaxart (NASDAQ:VXRT) Stock Price Passes Above 200 Day Moving Average of $0.82

Vaxart, Inc. (NASDAQ:VXRTGet Free Report)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.82 and traded as high as $1.16. Vaxart shares last traded at $1.08, with a volume of 2,088,339 shares.

Wall Street Analysts Forecast Growth

Separately, B. Riley raised shares of Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Wednesday, January 31st.

Read Our Latest Stock Report on Vaxart

Vaxart Stock Down 1.8 %

The firm has a market cap of $165.73 million, a P/E ratio of -1.86 and a beta of 0.44. The stock’s 50-day simple moving average is $1.04 and its 200 day simple moving average is $0.82.

Vaxart (NASDAQ:VXRTGet Free Report) last issued its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. The business had revenue of $3.25 million for the quarter, compared to analysts’ expectations of $0.45 million. Vaxart had a negative net margin of 2,141.68% and a negative return on equity of 99.74%. On average, research analysts forecast that Vaxart, Inc. will post -0.59 earnings per share for the current fiscal year.

Institutional Trading of Vaxart

Institutional investors have recently bought and sold shares of the company. Cantor Fitzgerald L. P. acquired a new position in shares of Vaxart during the second quarter valued at about $5,173,000. State Street Corp raised its holdings in shares of Vaxart by 23.9% during the first quarter. State Street Corp now owns 13,860,974 shares of the biotechnology company’s stock valued at $69,859,000 after purchasing an additional 2,673,332 shares during the period. Two Sigma Investments LP raised its holdings in shares of Vaxart by 217.1% during the fourth quarter. Two Sigma Investments LP now owns 2,634,716 shares of the biotechnology company’s stock valued at $2,532,000 after purchasing an additional 1,803,720 shares during the period. Millennium Management LLC raised its holdings in shares of Vaxart by 1,862.7% during the fourth quarter. Millennium Management LLC now owns 1,693,090 shares of the biotechnology company’s stock valued at $1,627,000 after purchasing an additional 1,606,826 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Vaxart during the fourth quarter valued at about $972,000. Institutional investors own 19.04% of the company’s stock.

About Vaxart

(Get Free Report)

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia.

Featured Articles

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.